FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...

NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad population the company had originally sought.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older.

Novavax gets FDA approval for its Covid-19 vaccine with limitations, triggering a $175 million payment from Sanofi under their partnership.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other vaccines, too.